CombiMatrix Announces Launches Microarray Testing for Stillbirth Analysis

CombiMatrix Corporation

announces the commercial launch of its SNP microarray genetic diagnostic testing for intrauterine fetal demise (IUFD), commonly known as stillbirth genetic testing.  "Our expansion into the underserved IUFD market is a logical extension of our current microarray genetic testing for miscarriage analysis," said Mark McDonough, President and Chief Executive Officer of CombiMatrix.  "We estimate the annual U.S. market for IUFD is $40 million and growing as more women choose to have children later in life.  Our consistent volume and revenue growth in our miscarriage product line since its introduction in the first quarter of 2013 gives us confidence in our commercial team's ability to capitalize on this expanded market opportunity.  We will continue to leverage our established relationships with hospital systems, OB/GYNs, maternal fetal medicine specialists and pathology laboratories to support this market expansion.  We also have the benefit of marketing tailwinds that include a growing portfolio of payer contracts and attractive reimbursement rates as well as the American College of